Latest News

Abacus Medicine postpones IPO

© Abacus Medicine


by tg

European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment". 

The announcement of the company came after Abacus Medicine published a prospectus last week and set the price range for its IPO between €14.50 and €16 per share.

The company had planned to file 3,586,207 shares in a primary offering to fund strategic growth initiatives to gain further market share across Europe. Abacus Medicine planed to further develop its manufacturing facilities in Hungary and the Netherlands, invest in growth and operational excellence, and use part of the proceeds for general corporate purposes. In a secondary offering, the company wanted to offer 1,365,926 shares to existing shareholders, including an over-allotment (645.930 ordinary shares) intended to create free float of approximately 45%. The company aimed at sizing the IPO of between approx. €71.8m and €79.2m with a post-IPO market capitalisation between approx. €160m to €176.6m.

The company's majority shareholder Wagner Family Holding ApS , which currently holds around 91.6% off Abacus Medicine's stock and which was expected to hold at least 51% post IPO, stepped back from the IPO plans after the market environment proved unfavourable.

Mogrifiy completes Series A financing round

The financing was led by Parkwalk Advisors and co-financed by Astellas Venture Management as well as 24Haymarket, co-Founder of Abcam PLC, Dr...

European COVID-19 antibody enters Phase III testing

Acording to Saye Khoo, Chief Investigator for the study, " VIR-7832 appears to stand up to the major circulating variants of SARS-CoV-2 in the...

B.1.1.7 variant associated with higher mortality

Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

ADCendo ApS raises €51m in Series A financing

The investment into the spin-off company from the BioInnovation Institute (BII) in Copenhagen was led by Novo Seeds and Ysios Capital, along with RA...

Janssen to pledge COVID-19 vaccine to African Union

The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral...

EU orders 100 million additional doses from Biontech

To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

Targeting SARS-CoV-2 differently

Using X-ray crystallography, Sebastian Günther and colleagues screened more than 5,000 drug compounds, identified seven compounds that bind to Mpro,...